Form 4: Design Therapeutics Chief Accounting Officer Awarded Stock Options

Design Therapeutics' Chief Accounting Officer, Julie Burgess, was granted stock options for 135,000 shares on January 2, 2025.

Summary

• Julie Burgess, the Chief Accounting Officer of Design Therapeutics, was granted stock options to purchase 135,000 shares of the company's common stock.
• The options have an exercise price of $6.17 per share.
• The options vest over a period of time, with 20% vesting on January 1, 2026, and the remaining 80% vesting in equal monthly installments over the following 36 months.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative or unusual activity.

Positives

• The granting of stock options aligns the interests of the Chief Accounting Officer with the long-term success of the company.
• The vesting schedule encourages continued service and performance from the officer.

Industry Context

Stock option grants are a common form of compensation for executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation across the biotechnology industry.
• Vesting schedules are also common, typically ranging from 3 to 5 years, with a portion vesting each year or month.
• The specific terms of the grant, such as the exercise price and vesting schedule, are often tailored to the individual executive and the company's performance goals.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it incentivizes the Chief Accounting Officer to contribute to the company's long-term success.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, insider trading, executive compensation, equity, Design Therapeutics, DSGN, Julie Burgess, Chief Accounting Officer